EP3386536A4 - Composition de conjugués d'agonistes-constructions d'anticorps et leurs procédés d'utilisation - Google Patents

Composition de conjugués d'agonistes-constructions d'anticorps et leurs procédés d'utilisation Download PDF

Info

Publication number
EP3386536A4
EP3386536A4 EP16873755.9A EP16873755A EP3386536A4 EP 3386536 A4 EP3386536 A4 EP 3386536A4 EP 16873755 A EP16873755 A EP 16873755A EP 3386536 A4 EP3386536 A4 EP 3386536A4
Authority
EP
European Patent Office
Prior art keywords
composition
methods
antibody construct
agonist conjugates
conjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16873755.9A
Other languages
German (de)
English (en)
Other versions
EP3386536A2 (fr
Inventor
Peter Armstrong Thompson
Badreddin EDRIS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Opi Vi- Ip Holdco LLC
Original Assignee
Opi Vi- Ip Holdco LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/173,075 external-priority patent/US20170158772A1/en
Application filed by Opi Vi- Ip Holdco LLC filed Critical Opi Vi- Ip Holdco LLC
Publication of EP3386536A2 publication Critical patent/EP3386536A2/fr
Publication of EP3386536A4 publication Critical patent/EP3386536A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP16873755.9A 2015-12-07 2016-12-07 Composition de conjugués d'agonistes-constructions d'anticorps et leurs procédés d'utilisation Withdrawn EP3386536A4 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562264260P 2015-12-07 2015-12-07
US15/173,075 US20170158772A1 (en) 2015-12-07 2016-06-03 Compositions of antibody construct - agonist conjugates and methods of use thereof
US201662371141P 2016-08-04 2016-08-04
PCT/US2016/065353 WO2017100305A2 (fr) 2015-12-07 2016-12-07 Composition de conjugués d'agonistes-constructions d'anticorps et leurs procédés d'utilisation

Publications (2)

Publication Number Publication Date
EP3386536A2 EP3386536A2 (fr) 2018-10-17
EP3386536A4 true EP3386536A4 (fr) 2019-07-31

Family

ID=59013332

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16873755.9A Withdrawn EP3386536A4 (fr) 2015-12-07 2016-12-07 Composition de conjugués d'agonistes-constructions d'anticorps et leurs procédés d'utilisation

Country Status (4)

Country Link
EP (1) EP3386536A4 (fr)
CA (1) CA3007311A1 (fr)
DE (1) DE212016000029U1 (fr)
WO (1) WO2017100305A2 (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018002757A8 (pt) 2015-08-13 2023-04-11 Merck Sharp & Dohme Composto, composição farmacêutica, e, métodos para induzir uma resposta imune, para induzir uma produção de interferon tipo i e para tratamento de um distúrbio
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
HRP20221263T1 (hr) 2016-03-18 2023-03-03 Immune Sensor, Llc Ciklički di-nukleotidni spojevi i postupci uporabe
CN115317603A (zh) 2016-07-07 2022-11-11 小利兰·斯坦福大学托管委员会 抗体佐剂缀合物
TN2020000159A1 (en) 2016-10-04 2022-04-04 Merck Sharp & Dohme BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
WO2018144955A1 (fr) * 2017-02-02 2018-08-09 Silverback Therapeutics, Inc. Compositions de produit de recombinaison-peptide et leurs méthodes d'utilisation
AR113224A1 (es) * 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
EP3621624B1 (fr) 2017-05-12 2023-08-30 Merck Sharp & Dohme LLC Composés dinucléotidiques cycliques en tant qu'agonistes sting
JP2020530838A (ja) 2017-08-04 2020-10-29 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． がん治療のためのベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニスト
AU2018311965A1 (en) 2017-08-04 2020-02-13 Merck Sharp & Dohme Llc Combinations of PD-1 antagonists and benzo[b]thiophene sting antagonists for cancer treatment
CN107365361B (zh) * 2017-08-21 2020-05-19 中国药科大学 与pd-l1结合的重复域锚定蛋白及其用途
EP3676278B1 (fr) * 2017-08-31 2023-04-12 Bristol-Myers Squibb Company Dinucléotides cycliques utilisés en tant qu'agents anticancéreux
CN111051328B (zh) * 2017-08-31 2023-11-03 百时美施贵宝公司 作为抗癌剂的环二核苷酸
US11707531B2 (en) * 2017-09-11 2023-07-25 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
WO2019051488A1 (fr) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. Composés, compositions et méthodes de traitement de maladie
AU2018364708A1 (en) 2017-11-10 2020-05-21 Takeda Pharmaceutical Company Limited Sting modulator compounds, and methods of making and using
US11685761B2 (en) 2017-12-20 2023-06-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
EP3505188A1 (fr) * 2017-12-29 2019-07-03 Invivogen Conjugués de dinucléotide pro-cycliques pour l'induction de la cytokine
CN111971277B (zh) 2018-04-03 2023-06-06 默沙东有限责任公司 作为sting激动剂的苯并噻吩及相关化合物
WO2019195063A1 (fr) 2018-04-03 2019-10-10 Merck Sharp & Dohme Corp. Composés aza-benzothiophènes utilisés en tant qu'agonistes de sting
WO2019227007A1 (fr) 2018-05-25 2019-11-28 Incyte Corporation Composés hétérocycliques tricycliques en tant qu'activateurs de sting
US10875872B2 (en) 2018-07-31 2020-12-29 Incyte Corporation Heteroaryl amide compounds as sting activators
WO2020028565A1 (fr) 2018-07-31 2020-02-06 Incyte Corporation Composés hétéroaryles tricycliques en tant qu'activateurs de sting
BR112021003472A2 (pt) 2018-09-06 2021-05-18 Daiichi Sankyo Company, Limited derivado de dinucleotídeo cíclico e conjugado de anticorpo-fármaco do mesmo
US11596692B1 (en) 2018-11-21 2023-03-07 Incyte Corporation PD-L1/STING conjugates and methods of use
WO2020190725A1 (fr) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugués ciblant le her2
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
CN114127082A (zh) 2019-05-09 2022-03-01 阿里戈斯治疗公司 作为sting调节剂的经修饰的环状二核苷化合物
EP3976061A4 (fr) * 2019-06-03 2023-07-12 The University of Chicago Méthodes et compositions pour le traitement du cancer avec des adjuvants ciblant le cancer
US20220233673A1 (en) 2019-06-04 2022-07-28 Institut Curie METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STxB) MONOMERS AND OLIGOMERS, AND USES THEREOF
CA3147890A1 (fr) 2019-07-19 2021-01-28 Immunesensor Therapeutics, Inc. Conjugues anticorps-agonistes de sting et leur utilisation en immunotherapie
US11155567B2 (en) 2019-08-02 2021-10-26 Mersana Therapeutics, Inc. Sting agonist compounds and methods of use
CN114630684A (zh) * 2019-09-03 2022-06-14 博尔特生物治疗药物有限公司 氨基喹啉化合物、免疫缀合物及其用途
WO2021110987A1 (fr) 2019-12-06 2021-06-10 Life & Soft Procédés et appareils permettant de diagnostiquer un cancer à partir d'acides nucléiques acellulaires
CN111233850B (zh) * 2020-01-21 2022-09-23 南开大学 含苯并噻唑氨基和杂芳基的萘酚衍生物与制备方法和用途
US11179473B2 (en) 2020-02-21 2021-11-23 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
CN115209921A (zh) 2020-03-06 2022-10-18 第一三共株式会社 包含新型环状二核苷酸衍生物的抗体药物偶联物
WO2021180972A1 (fr) 2020-03-13 2021-09-16 Hephaistos-Pharma Lipopolysaccharides (lps) détoxifiées, lps naturellement non toxiques, et leurs utilisations
CN115803032A (zh) 2020-05-15 2023-03-14 免疫传感器治疗股份有限公司 Sting激动剂与免疫检查点抑制剂的联合治疗
AU2021300362A1 (en) 2020-07-01 2023-02-23 ARS Pharmaceuticals, Inc. Anti-ASGR1 antibody conjugates and uses thereof
EP3943505A1 (fr) 2020-07-22 2022-01-26 Encefa Peptides cd31 de liaison à cd38 et leurs utilisations
JPWO2022050300A1 (fr) 2020-09-02 2022-03-10
WO2022097117A1 (fr) 2020-11-09 2022-05-12 Takeda Pharmaceutical Company Ltd. Conjugués anticorps-médicament
US20240033366A1 (en) 2020-12-02 2024-02-01 Institut Curie FUNCTIONALIZED SHIGA TOXIN B-SUBUNIT (STxB) PROTEINS AND CONJUGATES THEREOF
AU2022226419A1 (en) 2021-02-26 2023-09-07 Brenus Pharma Nonautologous multi-stressed cancer cells and uses thereof for vaccinating and treating cancers
AU2022315305A1 (en) 2021-07-23 2024-02-01 Immunesensor Therapeutics, Inc. Sting agonist combination treatments with cytokines
WO2023041717A1 (fr) 2021-09-16 2023-03-23 Aboleris Pharma Domaines de liaison anti-cd45rc humaine et leurs utilisations
WO2023109942A1 (fr) * 2021-12-17 2023-06-22 Jacobio Pharmaceuticals Co., Ltd. Constructions lieurs-composés comprenant de nouveaux composés utiles en tant qu'agonistes de sting et leurs utilisations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015103987A1 (fr) * 2014-01-10 2015-07-16 Shanghai Birdie Biotech, Inc. Composés et compositions pour traiter des tumeurs à her2 positif

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE920561A1 (en) * 1991-02-21 1992-08-26 Gilead Sciences Aptamer specific for thrombin and methods of use
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
KR20040068613A (ko) 1994-03-25 2004-07-31 이소테크니카 인코포레이티드 중수소화된 화합물 이를 포함하는 고혈압 치료용 조성물
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US8946387B2 (en) * 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
DK2844282T3 (da) * 2012-05-04 2019-07-15 Pfizer Prostata-associerede antigener og vaccine-baserede immunterapiregimener

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015103987A1 (fr) * 2014-01-10 2015-07-16 Shanghai Birdie Biotech, Inc. Composés et compositions pour traiter des tumeurs à her2 positif

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ADAM J. R. GADD ET AL: "Targeted Activation of Toll-Like Receptors: Conjugation of a Toll-Like Receptor 7 Agonist to a Monoclonal Antibody Maintains Antigen Binding and Specificity", BIOCONJUGATE CHEMISTRY, vol. 26, no. 8, 16 July 2015 (2015-07-16), US, pages 1743 - 1752, XP055455345, ISSN: 1043-1802, DOI: 10.1021/acs.bioconjchem.5b00302 *
SINGH S.K., LUISI D.L. & PAK R.H.: "Antibody-Drug Conjugates: Design, Formulationand Physicochemical Stability", PHARM. RES., vol. 32, 19 May 2015 (2015-05-19), pages 3541 - 3571, XP002792278 *

Also Published As

Publication number Publication date
WO2017100305A2 (fr) 2017-06-15
WO2017100305A8 (fr) 2017-09-08
CA3007311A1 (fr) 2017-06-15
WO2017100305A3 (fr) 2017-07-20
DE212016000029U1 (de) 2017-07-30
EP3386536A2 (fr) 2018-10-17

Similar Documents

Publication Publication Date Title
EP3386536A4 (fr) Composition de conjugués d'agonistes-constructions d'anticorps et leurs procédés d'utilisation
EP3383430A4 (fr) Anticorps et leurs méthodes d'utilisation
EP3504243A4 (fr) Anticorps anti-tim-3 et leurs utilisations
HK1257056A1 (zh) 抗dll3抗體藥物綴合物以及使用方法
EP3515478A4 (fr) Anticorps pour siglec-15 et leurs méthodes d'utilisation
EP3280441A4 (fr) Anticorps anti-sortiline et leurs méthodes d'utilisation
EP3383914A4 (fr) Anticorps anti-ox40 et leurs procédés d'utilisation
EP3397276A4 (fr) Anticorps et conjugués de ceux-ci
EP3177322A4 (fr) Anticorps anti-trem2 et leurs procédés d'utilisation
EP3151830A4 (fr) Conjugués anticorps anti-her2-maytansine et méthodes d'utilisation de ceux-ci
EP3316909A4 (fr) Anticorps anti-ntb-a ainsi que compositions et procédés associés
EP3363816A4 (fr) Anticorps anti-ox40 et son application
EP3383917A4 (fr) Nouveaux anticorps anti-claudine et méthodes d'utilisation
EP3283517A4 (fr) Anticorps anti-pacap et leurs utilisations
EP3134121A4 (fr) Nouveaux anticorps anti-rnf43 et méthodes d'utilisation
EP3394098A4 (fr) Anticorps anti-myostatine et procédés d'utilisation
EP3248005A4 (fr) Nouveaux composés conjugués de glycane et leurs méthodes d'utilisation
EP3386986A4 (fr) Conjugués porphyrine d'or-peg et procédés d'utilisation
EP3341021A4 (fr) Anticorps anti-alk et leurs procédés d'utilisation
EP3270965A4 (fr) Anticorps cd48 et conjugués de ceux-ci
EP3559042A4 (fr) Anticorps anti-lilrb3 et leurs procédés d'utilisation
EP3294341A4 (fr) Compositions et procédés de production de conjugués d'anticorps
EP3283493A4 (fr) Conjugués de texaphyrine-phospholipide et leurs procédés de préparation
EP3525583A4 (fr) Anticorps anti-c1s et leurs méthodes d'utilisation
EP3189079A4 (fr) Nouveaux anticorps anti-mfi2 et méthodes d'utilisation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20180706

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20190701

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/32 20060101ALI20190624BHEP

Ipc: A61K 39/395 20060101ALI20190624BHEP

Ipc: A61K 39/39 20060101ALI20190624BHEP

Ipc: C07K 16/28 20060101ALI20190624BHEP

Ipc: A61K 47/68 20170101ALI20190624BHEP

Ipc: A61K 39/00 20060101AFI20190624BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1261040

Country of ref document: HK

17Q First examination report despatched

Effective date: 20200213

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20200624